MYC
- Aliases
-
- BHLHE39
- Class E basic helix-loop-helix protein 39
- MRTL
- MYC
- Myc proto-oncogene protein
- Proto-oncogene c-Myc
- Transcription factor p64
- avian myelocytomatosis viral oncogene homolog
- bHLHe39
- c-Myc
- cmyc
- myc proto-oncogene protein
- myc-related translation/localization regulatory factor
- v-myc avian myelocytomatosis viral oncogene homolog
- v-myc myelocytomatosis viral oncogene homolog (avian)
- Description
- The oncogenic protein MYC, previously known as c-MYC, is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. It participates in the regulation of gene transcription of specific target genes. MYC binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Mutations, overexpression, rearrangement and translocation of the MYC gene have been associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma. Evidence shows that alternative translation initiations from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site result in the production of two isoforms with distinct N-termini.
Attributes
- QA State
- Curated
- Type
- Gene
- HGNC Name
- MYC
- Certifications
-
- None
- QA State for Breast
- Under Review
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
- Certifications
-
- None
- QA State for Lung
- Under Review
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
- Autoantibodies in lung cancer: possibilities for early detection and subsequent cure.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.
- Recurrent genomic gains in preinvasive lesions as a biomarker of risk for lung cancer.
- The state of molecular biomarkers for the early detection of lung cancer.
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.